Interim Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended		105 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (118,089)	$ 59,794	$ (12,639,357)
Adjustments to reconcile net loss to net cash used by operating activities	5,628	5,628	136,025
Depreciation of furniture and equipment		5,928	554,256
Stock-based compensation			3,025,776
Non-cash services			1,005,082
Amortization of discount on note	450	450	2,250
Warrant issued for legal services			46,154
Accounts payable paid with common stock			144,103
Non-cash beneficial conversion right			36,400
Non-cash impairment of intellectual property			568,913
Non-cash impairment of tenant improvements			383,535
Expenses paid by stockholder			32,755
Accrued interest reduced in settlement		1,385	1,385
Accounts payable written off			(569,812)
Accounts payable reduced in lease settlement			520,788
Gain on extinguishment of debt		(180,955)	(234,502)
Loss on disposal of furniture and equipment		(1,985)	133,403
Prepaid expenses and deposits	(7,670)	15,279	(17,073)
Increase (decrease) in liabilities
Accounts payable	37,988	31,965	591,380
Accrued interest			82,088
Accrued expenses	34,548	17,994	153,398
Net cash used by operating activities	(47,145)	(44,517)	(6,043,053)
CASH FLOWS FROM INVESTING ACTIVITIES:
Intellectual property acquisition			(715,528)
Cash from sales of equipment		1,985	109,450
Furniture and equipment acquisiton, net			(1,327,070)
Cash acquired on reverse acquistion			1,429
Net cash provided (used) by investing activities		1,985	(1,931,719)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes	38,825	131,800	1,337,244
Proceeds from convertible note allocated to warrant			3,000
Proceeds from note to fund insurance premiums	32,160	0	32,160
Advances from related party			112,625
Payments on note payable	(23,840)	(89,268)	(166,146)
Proceeds from sale of common stock			6,655,889
Net cash provided by financing activities	47,145	42,532	7,974,772
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Income taxes paid
Interest paid			50,142
NON CASH INVESTING AND FINANCING ACTIVITES
Note payable to related party converted to common stock			36,400
Issuance of note for insurance		21,332	69,000
Issuance of note in exchange for accounts payable			$ 275,000

CELLCYTE GENETICS CORP 10-Q